Translational andrology and urology · 2025
Low expression and significance of AOC1 in prostate adenocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Hong-Qun, Yan De-Lun, Hua Hao-Ming, Huang Cong, Sun Wei, Zhu Ya-Nan, Yu Na, Shen Jing, Ma Zhi-Hou, Tao Si-Zhen, Huang Yan, Gong You-Jie, Zhang Yang-Yang
Аннотация
BACKGROUND: Currently, amine oxidase copper-containing 1 (AOC1) is less studied in cancer. There are few studies on the relationship between AOC1 and prognosis in prostate cancer. This study explores the expression profile of AOC1 in normal prostate tissue and prostate cancer, and investigates the relationship between the expression of AOC1 and prognosis of prostate cancer.
METHODS: The expression of AOC1 in 101 prostate cancer tissues and 22 normal prostate tissues was detected by immunohistochemistry. The AOC1 protein levels in the urine and blood samples of patients with prostate adenocarcinoma were examined by independent samples t-test.
RESULTS: AOC1 had a low positive expression rate (4.0%, 4/101) in prostate adenocarcinoma tissues, which was significantly lower than that (90.9%, 20/22) in adjacent normal tissues. The cancer-specific survival (CSS) for AOC1-positive patients was significantly shorter than AOC1-negative cases (31.750±8.384 vs. 79.068±4.818 months, P<0.001). Cox multivariate regression analysis showed that AOC1 positivity was the only survival factor of both cancer-specific survival (P=0.005) and progression-free survival (P=0.01). The AOC1 protein levels in the urine and blood samples showed no significant differences between preoperative prostate cancer patients and three months after operation of prostate cancer (P=0.43, P=0.41, respectively).
CONCLUSIONS: AOC1 has low expression in prostate adenocarcinoma, and its positive expression may be associated with tumor prognosis.
METHODS: The expression of AOC1 in 101 prostate cancer tissues and 22 normal prostate tissues was detected by immunohistochemistry. The AOC1 protein levels in the urine and blood samples of patients with prostate adenocarcinoma were examined by independent samples t-test.
RESULTS: AOC1 had a low positive expression rate (4.0%, 4/101) in prostate adenocarcinoma tissues, which was significantly lower than that (90.9%, 20/22) in adjacent normal tissues. The cancer-specific survival (CSS) for AOC1-positive patients was significantly shorter than AOC1-negative cases (31.750±8.384 vs. 79.068±4.818 months, P<0.001). Cox multivariate regression analysis showed that AOC1 positivity was the only survival factor of both cancer-specific survival (P=0.005) and progression-free survival (P=0.01). The AOC1 protein levels in the urine and blood samples showed no significant differences between preoperative prostate cancer patients and three months after operation of prostate cancer (P=0.43, P=0.41, respectively).
CONCLUSIONS: AOC1 has low expression in prostate adenocarcinoma, and its positive expression may be associated with tumor prognosis.